Trial Summary
What is the purpose of this trial?
The purpose of this study is to explore how the dietary supplement L-Phenylalanine affects the production of the metabolite phenylpropionic acid (PPA) and changes in fungal populations in the gut microbiome.
Research Team
ID
Iliyan D Iliev, PhD
Principal Investigator
Weill Medical College of Cornell University
Eligibility Criteria
This trial is for healthy volunteers interested in how a dietary supplement, L-Phenylalanine, might affect their gut health. Specific eligibility criteria are not provided, but typically participants should be free from the conditions being studied and meet any additional requirements set by the researchers.Inclusion Criteria
I am over 18 years old.
Exclusion Criteria
I have not taken antibiotics in the last two weeks.
Allergy to L-Phenylalanine or individuals with phenylketonuria (PKU)
Pregnant or nursing women
See 3 more
Treatment Details
Interventions
- L-Phenylalanine (Amino Acid Supplement)
Trial OverviewThe study is testing the effects of a 500 mg L-Phenylalanine capsule on gut fungal populations and production of phenylpropionic acid (PPA) in healthy individuals to understand its potential benefits for gut microbiome health.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: HealthyExperimental Treatment1 Intervention
Participants will receive one bottle of L-Phenylalanine 500 mg Veg Capsule product on Day 0. All subjects will be asked to start taking the supplement on Day 1 continuing until Day 14. They will be asked to take 2x 500 mg capsules in the morning and 1x 500 mg capsule in the evening daily for 14 days.
L-Phenylalanine is already approved in Canada for the following indications:
Approved in Canada as L-Phenylalanine for:
- Dietary supplement
- Medical food for phenylketonuria management
Find a Clinic Near You
Who Is Running the Clinical Trial?
Weill Medical College of Cornell University
Lead Sponsor
Trials
1,103
Recruited
1,157,000+
Dr. Robert Min
Weill Medical College of Cornell University
Chief Executive Officer since 2024
MD, MBA
Dr. Adam R. Stracher
Weill Medical College of Cornell University
Chief Medical Officer since 2024
MD